FDA Moves to Drop Decades-Old Warnings From Menopause Hormone Therapy: What It Means

The short version: On November 10, 2025 the U.S. Food and Drug Administration announced it was initiating removal of the boxed warning from menopausal hormone therapy (MHT) products. On February 12, 2026 it approved the first six revised labels. The warnings pulled out of the box are those about cardiovascular disease, breast cancer and probable dementia. This is a change to what a label shouts at you from the top of the page. It is not new evidence that hormone therapy is safe for everyone, and it is not a reason, on its own, to start a drug.

What is a boxed warning, and what does removing one actually do?

A boxed warning — the "black box" — is the strongest safety statement the FDA can put on a prescription drug. It sits at the very top of the prescribing information, framed in a black border, before the drug's indication. It is designed to be the first thing a prescriber sees. In practice it also becomes the first thing a pharmacist mentions, the first thing a patient reads in the leaflet, and the thing a busy clinician remembers when a woman with hot flashes is in front of them and there are nine minutes left in the appointment.

Removing it does not delete the risk information. Cardiovascular, clotting and cancer risks are still described in the Warnings and Precautions sections of the label, and contraindications are unchanged. What removal does is stop the label from front-loading a warning the agency concluded was not proportionate to the evidence for the products concerned — particularly for women starting therapy near menopause, and for low-dose vaginal estrogen, where systemic absorption is minimal.

So the honest framing: the box came off. The biology did not change. Your risk profile did not change. What changed is the default posture of the conversation.

Why was the warning there? The Women's Health Initiative, and how it was read

The boxed warning descends almost entirely from one trial and the way its headlines travelled.

In July 2002, the Women's Health Initiative (WHI) stopped the estrogen-plus-progestin arm of its trial early. Published in JAMA, it reported hazard ratios of 1.29 for coronary heart disease, 1.41 for stroke, 2.13 for pulmonary embolism and 1.26 for invasive breast cancer, alongside reductions in colorectal cancer and hip fracture. Newspapers ran the relative numbers — "26% more breast cancer," "41% more strokes" — and a generation of women came off hormone therapy within months.

Two things about that reporting were misleading, and both are now uncontroversial among menopause specialists.

First, relative risk without absolute risk is close to meaningless. The same WHI paper gave the absolute figures, and they are much less dramatic. Per 10,000 women taking combined therapy for a year, the trial found roughly 7 more coronary events, 8 more strokes, 8 more pulmonary emboli and 8 more invasive breast cancers — against 6 fewer colorectal cancers and 5 fewer hip fractures. Eight extra breast cancers per 10,000 women per year is a real harm and should not be waved away. It is also a very different number from the one most people carried away.

Second, the trial population was not the population being treated. WHI was designed to test whether hormones prevented chronic disease in older women, not whether they relieved symptoms in women at menopause. The mean age in the estrogen-plus-progestin arm was 63.3 years, and only about a third of participants were aged 50–59. Many were more than a decade past their final period, with arteries that had already begun to stiffen and plaque. The results were then generalised to 52-year-olds with night sweats — a group in whom the risk-benefit arithmetic is not the same. This is the core of what is now called the timing hypothesis: starting hormone therapy close to menopause appears to carry a materially different risk profile than starting it in your late sixties.

The estrogen-alone arm makes the point sharply. In WHI's long-term follow-up published in JAMA in 2020, women who had had a hysterectomy and took conjugated estrogen alone had lower breast cancer incidence than placebo (HR 0.78) and lower breast cancer mortality (HR 0.60). The combined arm showed higher incidence (HR 1.28). Yet for two decades both products carried a breast cancer warning in the box.

What exactly did the FDA change?

The FDA's action followed an expert panel, a review of the scientific literature and a public comment period. The agency asked manufacturers of MHT products to submit revised labels, and 29 manufacturers submitted proposed labeling updates. The first approvals came on February 12, 2026 and covered four categories: systemic combination therapy, systemic estrogen-alone, systemic progestogen-alone, and topical vaginal estrogen. The changes are visible in the labels themselves: the current Bijuva prescribing information on DailyMed records, under Recent Major Changes, "Boxed Warning, Cardiovascular Disorders, Probable Dementia, Breast Cancer, and Endometrial Cancer removed 2/2026."

The vaginal estrogen change is arguably the most consequential and the least discussed. For years, a woman with painful sex, recurrent UTIs and vaginal atrophy — genitourinary syndrome of menopause — was handed a cream whose leaflet warned about strokes and dementia, because the label had been copied across from systemic products. Plenty of women read it and put the tube in a drawer. Removing that box corrects a warning that arguably never applied to the product. Read more in our guide to vaginal estrogen.

What did not change?

This is where careful reading matters, because the news coverage has been triumphalist in places.

• Systemic estrogen still raises the risk of venous thromboembolism and stroke in some women. That risk is dose- and route-dependent, and appears lower with transdermal delivery than with oral, but it is not zero and it is not a matter of opinion. See HRT pills vs patches vs gels.
• Combined therapy is still associated with a modest increase in breast cancer incidence with longer duration of use. The FDA moved the statement out of the box; it did not repeal the finding.
• Contraindications are unchanged. Hormone therapy is generally not appropriate for people with a history of estrogen-sensitive breast cancer, unexplained vaginal bleeding, active or prior VTE or stroke, active liver disease, or known clotting disorders. Removing a box does not make anyone eligible who was not eligible before.
• Timing still matters. The new label language explicitly points at the under-60 / within-10-years window. That is a statement about who the benefit-risk balance favours — not a promise it favours everyone in that window.
• Hormone therapy is not approved as a longevity or disease-prevention drug. It treats symptoms; bone protection is a recognised benefit. It is not a heart-attack prevention strategy, and the label still says so.

Is this good news or is it politics?

Both things can be true, and pretending otherwise is not honesty. The announcement came with unusually promotional framing from the Department of Health and Human Services, and some oncologists and epidemiologists have publicly worried that removing the box will be heard as "hormones are safe now." The Menopause Society's response was pointedly balanced: it welcomed removal of the box on low-dose vaginal estrogen, while stressing that systemic estrogen "still comes with potential risks in certain individuals that should be reviewed in detail with women initiating therapy."

Our read: the direction of the change is defensible on the evidence — the box was over-broad, it was copy-pasted onto vaginal products where it did not belong, and it was built on a trial whose population did not match the patients being denied treatment. The risk now is over-correction. A label is a regulatory document, not a personal recommendation.

When should you talk to a clinician about this?

This section matters more than the rest of the article. Nothing here is a reason to start, stop or change a medication on your own.

Book a conversation if:

• You have bothersome hot flashes, night sweats, sleep disruption or mood change and you were told years ago that hormone therapy was "too dangerous" without a discussion of your individual risk. That conversation deserves to be reopened.
• You have vaginal dryness, painful sex, urinary urgency or recurrent UTIs after menopause. Local vaginal estrogen is a different conversation from systemic HRT, and the label now reflects that.
• You are already on hormone therapy and have questions about whether to continue. Do not change your regimen based on a news story.
• You have a history of breast cancer, blood clots, stroke, heart attack, liver disease or unexplained bleeding. These do not automatically rule everything out, but they change the calculus and require a specialist, not a headline.

Seek care promptly — not "at your next appointment" — if you develop: any bleeding after menopause; a new breast lump; chest pain or shortness of breath; one-sided leg swelling or calf pain; sudden severe headache, visual change, facial droop or weakness on one side.

To make the appointment count, it helps to walk in with your symptoms quantified and your questions written down. Our menopause doctor report tool builds a one-page summary you can hand over, and questions to ask your doctor about HRT covers what to ask about route, dose and duration.

The practical bottom line

A boxed warning is a regulator's judgement about how loudly a risk should be announced. For two decades that judgement was shaped by a 2002 trial in women whose average age was 63, reported in relative terms, and applied to women in their early fifties. Correcting it is overdue.

But "the warning was disproportionate" and "the drug is right for you" are entirely different sentences. Hormone therapy remains a genuinely effective treatment for vasomotor symptoms and for the genitourinary changes of menopause, with real risks that depend on your age, your years since menopause, your route of administration, your uterus, and your history. The label change is a reason to have the conversation you may have been discouraged from having. It is not a reason to start a drug.

If you want the fuller picture first, start with our overview of hormone replacement therapy, the difference between estrogen-only and combined HRT, the myths that still circulate, and — if hormones are not for you — what the non-hormonal options actually deliver.